IGR Blood Cancer Drugs Market Кликнуть для чтения
  • Комментарии

IGR

Blood Cancer Drugs Market

Опубликовано в "Здоровье и фитнес, Бизнес", язык - English. 5 страниц.
The report on Blood Cancer Drugs Market by product (rituaxan/mabthera, gleevac/glivec, revlimid, velcade, tasigna, pomalyst, vidaza, kyprolis, adcetris, and others) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Blood Cancer Drugs Market is projected to grow at a CAGR between 10.5% to 11.5% in terms of value over the period of Еще
Показать тэги

Другие публикации «IGR»

Посмотреть все публикации